Habegger, K.M.* ; Stemmer, K. ; Cheng, C.* ; Müller, T.D. ; Heppner, K.M.* ; Ottaway, N.* ; Holland, J.* ; Hembree, J.L.* ; Smiley, D.* ; Gelfanov, V.* ; Krishna, R.* ; Arafat, A.M.* ; Konkar, A.* ; Belli, S.* ; Kapps, M.* ; Woods, S.C.* ; Hofmann, S.M. ; D'Alessio, D.* ; Pfluger, P.T. ; Perez-Tilve, D.* ; Seeley, R.J.* ; Konishi, M.* ; Itoh, N.* ; Kharitonenkov, A.* ; Spranger, J.* ; DiMarchi, R.D.* ; Tschöp, M.H.
Fibroblast growth factor 21 mediates specific glucagon actions.
Diabetes 62, 1453-1463 (2013)
Glucagon, an essential regulator of glucose homeostasis, also modulates lipid metabolism and promotes weight loss, as reflected by the wasting observed in glucagonoma patients. Recently, coagonist peptides that include glucagon agonism have emerged as promising therapeutic candidates for the treatment of obesity and diabetes. We developed a novel stable and soluble glucagon receptor (GcgR) agonist, which allowed for in vivo dissection of glucagon action. As expected, chronic GcgR agonism in mice resulted in hyperglycemia and lower body fat and plasma cholesterol. Notably, GcgR activation also raised hepatic expression and circulating levels of fibroblast growth factor 21 (FGF21). This effect was retained in isolated primary hepatocytes from wild-type (WT) mice, but not GcgR knockout mice. We confirmed this link in healthy human volunteers, where injection of natural glucagon increased plasma FGF21 within hours. Functional relevance was evidenced in mice with genetic deletion of FGF21, where GcgR activation failed to induce the body weight loss and lipid metabolism changes observed in WT mice. Taken together, these data reveal for the first time that glucagon controls glucose, energy, and lipid metabolism at least in part via FGF21-dependent pathways.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Increases Energy-expenditure ; Ppar-alpha ; Insulin Sensitivity ; Body-weight ; Metabolism ; Mice ; Fgf21 ; Fibroblast-growth-factor-21 ; Pharmacology ; Degradation
Keywords plus
Language
english
Publication Year
2013
Prepublished in Year
HGF-reported in Year
2013
ISSN (print) / ISBN
0012-1797
e-ISSN
1939-327X
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 62,
Issue: 5,
Pages: 1453-1463
Article Number: ,
Supplement: ,
Series
Publisher
American Diabetes Association
Publishing Place
Alexandria, VA.
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30201 - Metabolic Health
Research field(s)
Helmholtz Diabetes Center
PSP Element(s)
G-502200-001
G-500690-001
G-502390-001
Grants
Copyright
Erfassungsdatum
2013-01-28